[{"id":"d057f56b-f783-458b-9509-43b66fe279f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01658969","created_at":"2021-03-29T21:52:20.526Z","updated_at":"2024-07-02T16:37:27.186Z","phase":"Phase 2","brief_title":"Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery","source_id_and_acronym":"NCT01658969","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Undisclosed HER2Bi-armed ATC • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2016-12-07"}]